CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+13.7%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$339M
AUM Growth
+$339M
(+3.2%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-3.5%
Top 10 Holdings %
Top 10 Hldgs %
55.99%
Holding
38
New
12
Increased
4
Reduced
11
Closed
11
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$29.7M |
| 2 |
Agilent Technologies
A
|
$17.9M |
| 3 |
Eli Lilly
LLY
|
$15.3M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$15.2M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$13.1M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$22.5M |
| 2 |
Merck
MRK
|
$21.7M |
| 3 |
Amgen
AMGN
|
$20.1M |
| 4 |
Biogen
BIIB
|
$17.8M |
| 5 |
Kenvue
KVUE
|
$17.5M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
26
Avadel Pharmaceuticals
AVDL
$1.45B
| $5.05M | 1.49% |
385,172
-347,829
| -47% | -$4.56M |
|
27
Ionis Pharmaceuticals
IONS
$9.11B
| $3.9M | 1.15% |
97,300
-62,866
| -39% | -$2.52M |
|
|
28
Amgen
AMGN
$154B
| – | – |
-64,201
| Closed | -$20.1M |
|
29
Avantor
AVTR
$9.01B
| – | – |
-400,000
| Closed | -$8.48M |
|
|
30
Biogen
BIIB
$20.2B
| – | – |
-76,726
| Closed | -$17.8M |
|
|
31
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
-273,533
| Closed | -$22.5M |
|
32
CRISPR Therapeutics
CRSP
$4.78B
| – | – |
-201,497
| Closed | -$10.9M |
|
33
Cytokinetics
CYTK
$5.96B
| – | – |
-236,900
| Closed | -$12.8M |
|
34
Evolus
EOLS
$479M
| – | – |
-465,300
| Closed | -$5.05M |
|
|
35
Kenvue
KVUE
$39.6B
| – | – |
-960,400
| Closed | -$17.5M |
|
|
36
Merck
MRK
$212B
| – | – |
-175,600
| Closed | -$21.7M |
|
37
Pfizer
PFE
$141B
| – | – |
-185,200
| Closed | -$5.18M |
|
38
Teva Pharmaceuticals
TEVA
$21.4B
| – | – |
-911,900
| Closed | -$14.8M |
|